Cytokeratin 19Catalog number: CK119
Cytokeratin 19 is found in most simple epithelia and non keratinised squamous epithelia with predominant focal reactivity. RCK108 stains practically all epithelial tumours, especially adenocarcinoma. It is negative in hepatocellular carcinoma (4). Most medullary, weakly differentiated ductal carcinoma are also CK19-negative (3). Cytokeratins are a group of water insoluble filament proteins, which are constituents of the cytoskeleton of epidermal cells and other epithelial cells. By gel electrophoretic analysis up to now 20 different cytokeratins have been characterized. They have been divided into basic and acid subfamilies and may also be distinguished by their molecular weights and their tissue distribution. The most frequently used nomenclature has been published by R. Moll et al. (1982). Antibody RCK108 reacts with a 40 kDa keratin (Cytokeratin 19) in immunoblot.
Immunogen: Cell line T24
Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art. No. PU002, if further dilution is required.
Purification Method: Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art. No. PU002, if further dilution is required.
Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005).
Species Reactivity: Human, Zebrafish
Incubation Time: 60 min at RT
Working Concentration: (liquid conc.) 1:10 - 1:50
Pre-Treatment: Heat pre-treatment of formalin-fixed tissue with Unmasking Fluid C or G (Art. No. DE000 and DE007)
Positive Control: Glandular epithelia
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Moll R., Franke W.W., Schiller D.L., Geiger B., and Krepler R. (1982) The Catalog of Human Cytokeratins: Patterns of Expression in Normal Epithelia, Tumors and Cultured Cells. Cell 31; 11 ff. 2. Smedts F., Ramaekers F., Robben H., et al. (1990) Changing patterns of keratin expression during progression of cervical intraepithelial neoplasia. Am J. Pathol. 136,3; 657-668. 3. Dalal P. and Shousha S. (1995) Keratin 19 in paraffin sections of medullary carcinoma and other benign and malignant breast lesions. Mod. Pathol. 8(4); 413-416. 4. Kwaspen F.H., Smedts F.M., Broos A., Bulten H., Dedie W.M., and Raemaekers F.C. (1997) Reproducible and highly sensitive detection of the broad spectrum epithelium marker keratin 19 in routine cancer diagnosis. Histopathol. 31(6); 503-516.
Safety Datasheet(s) for this product: